FEATUREDLatestScienceTechnologyTOP STORIES

How Histotripsy is Transforming Cancer Treatment

Focused sound waves can mechanically destroy some liver tumours without surgery. It is a promising new option, though long-term outcomes are still being studied

Update (10 November 2026): Since this article was first written, HistoSonics was acquired for $2.25 billion (August 2025), according to the Focused Ultrasound Foundation, which also reports European regulatory approval for liver tumours. Researchers have reported one-year data suggesting around 90% tumour control, and the company has submitted an application to the FDA for a kidney tumour indication. This is early-stage evidence for a new treatment, not a cure.

In the sterile corridors of the University of Michigan Medical Centre, a new kind of treatment is being used. In place of a scalpel, the tool is focused sound.

This approach, known as histotripsy, is an important development in non-invasive treatment of liver tumours. Unlike diagnostic ultrasound, which creates images, histotripsy uses focused ultrasound pulses to mechanically break down targeted tissue.

The Science Behind the Sound

The technique employs high-intensity, focused ultrasound pulses delivered from outside the body to create microscopic gas bubbles within targeted cancerous tissue. As these bubbles rapidly expand and collapse in a process called acoustic cavitation, they generate mechanical forces powerful enough to break tumour cells down into cellular debris.

This cavitation process mechanically destroys tissue, rendering it into acellular debris that can be safely reabsorbed by the body. What makes the approach notable is its precision: the sound waves can be focused with millimetre accuracy, which is intended to limit damage to surrounding healthy tissue, although some risk to nearby structures remains.

Dr Zhen Xu, a biomedical engineer at the University of Michigan, is a pioneer of the technology, which her laboratory developed over many years before it was commercialised by HistoSonics.

Landmark Clinical Results

The main evidence comes from the #HOPE4LIVER clinical trial. It included 44 patients in the United States and Europe, and in 42 of them (95%) the treatment was technically successful, meaning the targeted tumour was covered by the treatment zone on imaging, as Michigan Medicine reported. Technical success is not the same as cure or improved survival: the trial was a single-arm study that did not measure survival.

The procedure involves no surgical incision or radiation, and no chemotherapy. It can be performed with a short hospital stay, and many patients return to normal activities within days, although it is still a medical procedure with risks.

The trial reported a 6.8% rate of major complications, which fell within the ranges reported for other established local treatments for liver tumours. Longer-term follow-up is still needed to show how durable the results are; early one-year data have been reported by researchers, but this is still a relatively young therapy.

Beyond Destruction: Awakening the Immune System

One of histotripsy’s most intriguing aspects lies not just in its ability to destroy tumours, but in what happens afterwards. Preclinical (laboratory and animal) studies suggest that histotripsy may not only destroy tumours but also stimulate the immune system to recognise and attack cancer cells. Whether this reduces the chance of recurrence in people has not been established.

The idea is that the mechanical disruption of tumour cells releases cellular contents that could act as signals to the immune system. This remains a hypothesis supported mainly by preclinical work.

If confirmed in patients, this could allow benefits beyond the treated site, and researchers are studying combinations with immunotherapy, but it should not be assumed.

From Laboratory to Hospital: The Clinical Reality

The journey from experimental technique to clinical use reached a milestone in October 2023, when the US FDA granted De Novo marketing authorisation to the Edison system for the non-thermal destruction of liver tumours. The system is produced by HistoSonics, a company with ties to the University of Michigan.

Since authorisation, a growing number of hospitals have begun offering the treatment, and a published safety analysis of the early international experience (230 cases) has reported on its safety in routine use.

For some patients with liver tumours who are not candidates for surgery, histotripsy offers an additional option. Whether it is suitable depends on the size, number and location of the tumours, and should be discussed with a specialist team.

Expanding Horizons: Beyond Liver Cancer

While liver tumours have served as the initial proving ground for histotripsy, researchers are exploring other organs, including the kidney and the pancreas. These applications are investigational and not yet approved, and nobody should assume that results in the liver will carry over.

In principle, histotripsy could be applied to solid tumours that can be reached by focused sound waves, but ultrasound cannot pass through air or bone, so many locations are hard to treat. Each new organ and tumour type requires its own clinical evidence.

The Patient Experience

For patients, the experience differs markedly from surgery. The pulses are delivered through the skin under imaging guidance while the patient is under anaesthesia, and the sound itself is not felt.

The absence of surgical incisions means no surgical scars and generally shorter recovery than major surgery, though complications such as pain, bleeding or infection can still occur, as the trial’s complication rate shows.

Shorter recovery times may reduce healthcare costs and caregiver burden, although cost-effectiveness has yet to be established.

Technical Precision: The Art and Science of Acoustic Targeting

The technical sophistication underlying histotripsy reflects decades of research into the physics of ultrasound and its biological effects. The creation of microbubble clusters occurs through three distinct mechanisms: intrinsic threshold activation, shock scattering from longer pulses, and amplification of existing nuclei.

This multi-faceted approach to cavitation generation allows clinicians to tailor treatments to specific tumour characteristics and anatomical locations. Real-time imaging guidance ensures that the destructive forces are precisely focused on malignant tissue whilst preserving surrounding healthy structures.

The non-thermal nature of the process is a potential advantage over other energy-based treatments. While techniques such as radiofrequency ablation or high-intensity focused ultrasound rely on heat to destroy tissue, histotripsy’s mechanical approach avoids the heat-sink effect and thermal injury, though the cavitation itself must still be carefully controlled.

Looking Forward: The Future of Sound-Based Medicine

As histotripsy continues to evolve, researchers are exploring ways to enhance its effectiveness and expand its applications. Current investigations focus on optimising treatment protocols, improving patient selection criteria, and combining histotripsy with other therapeutic approaches such as immunotherapy.

The success of histotripsy has also sparked interest in other sound-based medical applications. The principles underlying this technology could potentially be adapted for drug delivery, breaking up blood clots, or treating non-cancerous conditions such as kidney stones or benign tumours.

Histotripsy is part of a broader shift towards precise, targeted, minimally invasive approaches to treating cancer.

A New Chapter in Cancer Care

Histotripsy is a welcome addition to the options for treating liver tumours: precise, non-thermal and non-invasive.

For some patients diagnosed with cancer of or in the liver, it offers a less invasive alternative. It is not a cure for cancer in general, and how well it works over the long term compared with established treatments is still being studied. Anyone considering treatment should speak to their oncology team.

Focused sound has become a clinical tool against liver tumours, and it will be interesting to see how far the evidence supports its wider use.

This article is for general information and is not medical advice. The HOPE4LIVER results have been published in the peer-reviewed literature, and histotripsy continues to be evaluated for additional tumour types in clinical trials.

We’d love your questions or comments on today’s topic!

For more articles like this one, click here.

Thought for the day:

Reconciliation is a part of the healing process, but how can there be healing when the wounds are still being inflicted?   N. K. Jemisin

Leave a Reply

Your email address will not be published. Required fields are marked *